Illumina (ILMN)
(Delayed Data from NSDQ)
$130.14 USD
+2.41 (1.89%)
Updated Mar 18, 2024 04:00 PM ET
After-Market: $130.17 +0.03 (0.02%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$130.14 USD
+2.41 (1.89%)
Updated Mar 18, 2024 04:00 PM ET
After-Market: $130.17 +0.03 (0.02%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
Zacks News
Is Invesco S&P 500 Equal Weight Health Care ETF (RSPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RSPH
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RSPH)?
by Zacks Equity Research
Sector ETF report for RSPH
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PBE
Should Invesco S&P 500 Equal Weight ETF (RSP) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for RSP
Is Invesco S&P 500 Equal Weight ETF (RSP) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RSP
Illumina (ILMN) Rides on NGS Portfolio Expansion Amid Macro Woe
by Zacks Equity Research
In reproductive health, Illumina (ILMN) primarily focuses on driving noninvasive prenatal testing (NIPT) adoption globally.
Illumina (ILMN) Q4 Earnings Surpass Estimates, Margin Down
by Zacks Equity Research
Illumina (ILMN) Q4 revenues increase year over year, driven by NovaSeq X instrument and consumables sales.
Illumina (ILMN) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Illumina (ILMN) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
HRMY or ILMN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HRMY vs. ILMN: Which Stock Is the Better Value Option?
Seeking Clues to Illumina (ILMN) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics
by Zacks Equity Research
Get a deeper insight into the potential performance of Illumina (ILMN) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Illumina (ILMN) Shares Down 1.2% Post Preliminary Q4 Results
by Zacks Equity Research
Illumina's (ILMN) fourth-quarter 2023 results are likely to reflect the impacts of the adoption of its new generation of distributed liquid biopsy assay.
Is Invesco S&P 500 Equal Weight Health Care ETF (RSPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RSPH
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Illumina (ILMN) Extends Partnership to Advance Cancer Test
by Zacks Equity Research
Illumina (ILMN) aims to work with other pharmaceutical industry leaders to enhance and expand the utility of its WGS MRD assay.
Here's Why You Should Retain Illumina (ILMN) Stock for Now
by Zacks Equity Research
Investors are optimistic about Illumina's (ILMN) strength in the genomics market and strong solvency position.
Illumina (ILMN) Expands Globally Despite Macroeconomic Woes
by Zacks Equity Research
The NovaSeq X launch strengthens Illumina's (ILMN) competitive position in high-throughput sequencing.
Illumina (ILMN) Launches Initiative on Pathogen Sequencing
by Zacks Equity Research
Illumina (ILMN) introduces a new initiative to drive more equitable access to genomics globally.
LGND or ILMN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
LGND vs. ILMN: Which Stock Is the Better Value Option?
Company News for Nov 13, 2023
by Zacks Equity Research
Companies In The News Are: ILMN, CTRE, WPM, FLO.
Illumina (ILMN) Q3 Earnings Surpass Estimates, '23 View Cut
by Zacks Equity Research
Illumina (ILMN) reports solid earnings in the third quarter of 2023 amid a challenging macro environment.
Illumina (ILMN) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
Although the revenue and EPS for Illumina (ILMN) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Seeking Clues to Illumina (ILMN) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Illumina (ILMN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2023.
Earnings Preview: Illumina (ILMN) Q3 Earnings Expected to Decline
by Zacks Equity Research
Illumina (ILMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LGND vs. ILMN: Which Stock Is the Better Value Option?
by Zacks Equity Research
LGND vs. ILMN: Which Stock Is the Better Value Option?